---
title: "Incyte stock falls 6% amid Q4 earnings, 2025 forecast"
date: "2025-02-10 20:09:27"
summary: "Shares of Incyte (NASDAQ:INCY) fell 6% Monday after the company released its Q4 earnings report and 2025 sales forecast. The biotech company reported that Q4 revenue rose 16% year-over-year to $1.18B, with non-GAAP EPS $1.46. Analysts, on average, were expecting non-GAAP EPS of $1.55 on revenue of $1.15B. For full-year..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491861668/image_1491861668.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Shares of Incyte (NASDAQ:[INCY](https://seekingalpha.com/symbol/INCY "Incyte Corporation")) fell 6% Monday after the company released its Q4 earnings report and 2025 sales forecast. 

The biotech company reported that Q4 revenue rose 16% year-over-year to $1.18B, with non-GAAP EPS $1.46. Analysts, on average, were expecting non-GAAP EPS of $1.55 on revenue of $1.15B. 

For full-year 2024, revenue climbed 15% year-over-year to $4.2B, in line with the consensus estimate. Net revenues for the company's top-selling drug, Jafaki, were $2.8B, while net revenues for its second bestseller, Opzelura, were $508M.

Looking ahead, Incyte (NASDAQ:[INCY](https://seekingalpha.com/symbol/INCY "Incyte Corporation")) said it anticipates 2025 net revenues of $2.925B to $2.975B for Jafaki and net revenues of $630M to $670M for Opzelura. Other oncology product net revenues are expected in the range of $415M to $455M, [according to a statement.](https://seekingalpha.com/pr/19996334-incyte-reports-2024-fourth-quarter-and-year-end-financial-results-provides-2025-financial)

Analysts, on average, were expecting Incyte ([INCY](https://seekingalpha.com/symbol/INCY "Incyte Corporation")) to report 2025 revenue of $4.65B.

[seekalpha](https://seekingalpha.com/news/4405693-incyte-stock-falls-percent-amid-q4-earnings-2025-forecast)
